Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Article 3 Stocks Under $5 With Strong Analyst Upside PotentialAuthored by Chris Markoch. Posted: 2/24/2026. 
Key Points - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
While many investors are rotating out of speculative penny stocks, others still embrace their risk-reward trade-off. Stocks trading under $5 carry inherent risk: many are unprofitable, some generate little to no revenue, and most are small-cap companies that have been beaten up in recent years. Even with the Russell 2000 showing some recovery, that improvement has not been broad-based across the small-cap sector. That may change in 2026 if the economic outlook continues to improve, drawing money back into speculative names. As always, quality matters. One way to screen for quality is to focus on names that enjoy positive analyst sentiment. The three stocks below fit that bill. Each lets investors start a sizable position with a modest outlay while still offering meaningful upside potential over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging-market stocks are expected to be among the winners in 2026. That hasn't been the case so far for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% year-to-date. The Singapore-based company operates a super app that blends technology, e-commerce, and fintech services. One reason behind the recent pullback is its proposed merger with Indonesian ride-hailing rival GoTo. The deal is not final and remains subject to potential legislative changes in Indonesia that could limit Grab's earnings potential there. Grab also missed on the top line in its Q4 2025 earnings report. Some context is important: revenue rose 19% year-over-year, and the year marked the company's first full year of profitability. Analysts forecast roughly 120% earnings growth over the next 12 months. That helps explain the bullish sentiment. GRAB has a consensus price target of $6.47, implying about 54% upside from its current price. High-Risk Biotech With Platform Potential Penny-stock investors often look to the biotechnology sector to balance high risk with high reward. One company to watch is Vaxart Inc. (OTCMKTS: VXRT), the only stock on this list that meets the classic penny-stock definition. At the time of writing it traded at just over $0.60 per share. VXRT has limited analyst coverage, but the lone analyst to rate it in the past 12 months lists it as a Buy with a $2 price target. It's not uncommon for analysts to overlook certain biotechs. Vaxart is a clinical-stage company, so its candidates remain in clinical trials. The potential upside, however, is clear: Vaxart is developing oral vaccines for influenza, norovirus, and COVID-19. Beyond convenience and avoiding needles, the company says its platform may elicit a broader immune response that could provide wider protection. Institutional ownership of VXRT is low—about 18%—but, by dollar volume, inflows outnumber outflows nearly 10:1, which is worth noting. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down about 33% so far in 2026, but a 12-month view provides a different perspective: TDUP is up more than 66% over the last year, suggesting the current move may be a routine pullback as investors shy away from unprofitable companies. "Yet" may be the operative word. ThredUp runs an online consignment and thrift platform that appears to be resonating with Gen Z. In its most recent quarter, revenue rose 12.5% year-over-year. The company cites a GlobalData 2025 market survey projecting the U.S. secondhand market's gross merchandise value to grow at a compound annual growth rate (CAGR) of 9% through 2029. Institutional ownership is high—about 89%—and buying has exceeded selling two-to-one in dollar terms and three-to-one by number of buyers versus sellers. That said, short interest sits around 17%, which can add near-term volatility. The consensus price target from six analysts is $12.50, implying upside of more than 190% from the stock's current price.
| 
